Globalepolicy.org is a free to access global medical news service for the consumer, professional and researcher.


             
 

Background: A treatment algorithm and screening examination have been developed to guide patient management and prospectively determine potential for highly active individuals to succeed with nonoperative care after anterior cruciate ligament rupture.

Objective: To prospectively characterize and classify the entire population of highly active individuals over a 10-year period and provide final outcomes for individuals who elected nonoperative care.

Methods: Inclusion criteria included presentation within 7 months of the index injury and an International Knee Documentation Committee level I or II activity level before injury. Concomitant injury, unresolved impairments, and a screening examination were used as criteria to guide management and classify individuals as noncopers (poor potential) or potential copers (good potential) for nonoperative care.

Results: A total of 832 highly active patients with subacute anterior cruciate ligament tears were seen over the 10-year period; 315 had concomitant injuries, 87 had unresolved impairments, and 85 did not participate in the classification algorithm. The remaining 345 patients (216 men, 129 women) participated in the screening examination a mean of 6 weeks after the index injury. There were 199 subjects classified as noncopers and 146 as potential copers. Sixty-three of 88 potential copers successfully returned to preinjury activities without surgery, with 25 of these patients not undergoing anterior cruciate ligament reconstruction at the time of follow-up.

Conclusion: The classification algorithm is an effective tool for prospectively identifying individuals early after anterior cruciate ligament injury who want to pursue nonoperative care or must delay surgical intervention and have good potential to do so.



NAVIGATION


         

 

Scientists at the Johns Hopkins Kimmel Cancer Center have used data from the whole genome sequencing of cancer patients to develop individualized blood tests they believe can help physicians tailor patients’ treatments. The genome-based blood tests, believed to be the first of their kind, may be used to monitor tumor levels after therapy and determine cancer recurrence…

 

Using lasers and nanoparticles, scientists at Rice University have discovered a new technique for singling out individual diseased cells and destroying them with tiny explosions. The scientists used lasers to make “nanobubbles” by zapping gold nanoparticles inside cells…

 

A new testing method is being developed to detect cancer soon after the tumor has formed. It will identify characteristic substances in the blood which accompany a certain type of tumor. The first steps in the development have already been completed. The earlier the doctor finds the tumor, the better the patient’s chances of recovery…

 

New advances for the detection of cancer led by Rafael V. Davalos of the Virginia Tech-Wake Forest School of Biomedical Engineering and Science (SBES) are featured as the cover story in the January 19, 2010 Royal Society of Chemistry’s magazine, Lab on a Chip, the premier journal for researchers in microfluidics. Microfluidics is the behavior of fluids at the microscale level…

 

A new technique to catch cancer early has taken an important step forward thanks to the National Physical Laboratory (NPL). NPL’s ‘phantoms’ will ensure an exciting new screening technique can be relied upon by hospitals to identify early signs of cancer…

 

The world’s smallest flexible microscope is diagnosing some big diseases and allowing physicians to treat patients on the spot. Dr. Michel Kahaleh, associate professor of medicine in the Division of Gastroenterology and Hepatology at the University of Virginia Health System, is the only physician in Virginia currently using probe-based confocal laser endomicroscopy (pCLE)…

 

A chemotherapy software solution that enables patients to become more involved in managing their own care has been successfully rolled out across a network of hospitals in the UK. The Thames Valley Cancer Network has implemented Aria for Medical Oncology™ from Varian Medical Systems (NYSE: VAR) and already has more than 850 clinical staff routinely using the system…

 

Image-guided radiofrequency ablation (RFA), a minimally invasive cancer treatment which can be performed in the outpatient setting, significantly reduced the level of pain experienced by cancer patients with bone (osseous) metastases, limiting the need for strong narcotic pain management, and supporting improved patient frame of mind, according to results of an American College…

 

Co-Founder, Andrea Califano, Ph.D., and Wei Keat Lim, Ph.D., Head of Computational Systems Biology at Therasis, along with a team of scientists at Columbia University, have reported in the journal Nature the identification of two genes that, when simultaneously activated, cause the most lethal form of glioblastoma, an aggressive brain tumor…

 

The California Institute of Technology (Caltech) and the University of California, Los Angeles (UCLA) have announced the establishment of the Joint Center for Translational Medicine (JCTM), which will advance experimental research into clinical applications, including the diagnosis and therapy of diseases such as cancer…




March 2010
Mon Tue Wed Thu Fri Sat Sun
« Feb    
1234567
891011121314
15161718192021
22232425262728
293031